Shanghai Securities News China Securities(Reporter Zhang Xue) On October 30, Livzon Pharmaceutical Group announced that its developed quadrivalent recombinant protein...influenzaThe LZSN2401 vaccine recently completed vaccination of the first cohort of subjects in its Phase I clinical trial, and subsequent cohort enrollment has successfully commenced. This vaccine is the world's first adjuvanted quadrivalent recombinant protein influenza vaccine, and its development deeply integrated artificial intelligence.The technology, along with a significant breakthrough in adjuvant systems, promises to provide better protection for influenza prevention and control, especially for the elderly.

According to the company, in the development of LZSN2401, Livzon Pharmaceutical applied artificial intelligence technology systems to process development and analysis method optimization, which greatly improved R&D efficiency and product quality, fully demonstrating the company's strategic direction of using artificial intelligence to promote R&D efficiency in recent years.

Qualcomm utilizes AI algorithms to analyze key process parameters.Through quantitative simulation and intelligent screening, the team optimized a process route that would have taken more than six months under the traditional model within three months, shortening the overall R&D cycle by more than 50%. The optimized antigen expression level increased by up to four times compared to the original process, the product yield increased by six times, and the host protein residue was reduced by up to 98%, laying a solid foundation for the large-scale production of vaccines.

Another major highlight is that LZSN2401 uses a novel CD-A adjuvant developed in-house, which can significantly enhance both humoral and cellular immune responses, and more precisely address the needs of the elderly population.

This adjuvant system not only effectively enhances antigen uptake and immune cell recruitment, but also achieves highly efficient immune activation at low antigen doses, effectively avoiding the potential risks associated with high-dose vaccines. Preclinical studies have shown that this vaccine induces neutralizing antibody levels 3 to 5 times higher in mouse models than traditional split vaccines, demonstrating stronger protective potential for immunocompromised populations.

https://finance.eastmoney.com/a/202510313551794863.html